Becton, Dickinson and Company (BD) has acquired resorbable polymer technology provider Tepha for an undisclosed sum.
The acquisition of Tepha will allow BD to drive new innovations in soft tissue repair and regeneration.
Tepha’s resorbable polymer (Poly 4-hydroxybutyric acid, P4HB) technology platform is expected to boost the growth of BD’s surgical mesh portfolio.
The acquisition will also allow BD to strategically integrate a significant supply chain component into its existing Phasix Mesh products.
The deal also includes the acquisition of Tepha’s GalaFLEX portfolio, which is based on the novel P4HB polymer.
GalaFLEX products, which serve as bioresorbable scaffold for soft tissue support, enables to repair, elevate and reinforce deficiencies where weakness or voids exist that need the addition of material to secure the desired surgical outcome.
Tepha’s technology will be used by BD Interventional segment to extend its potential to other medical applications.
BD Surgery worldwide president Kevin Kelly said: “Tepha’s proprietary polymer is used in BD’s current Phasix Mesh products and is the key technology that enables our products to provide short-term support for soft tissue repairs, while enabling rapid tissue ingrowth and reabsorbing into the body over time.
“The acquisition — including its current and potential applications — will help ensure BD can continually provide physicians with the latest technology to treat their patients.”
For BD, Tepha is the sixth tuck-in acquisition that it has closed in fiscal 2021.
Recently, the company has acquired San Francisco-based needle-free blood draw technology provider Velano Vascular.
